Financial Advantage Advisors

Ken Mathis is the President and carries full portfolio management authority. The firm uses no investment committee structure and no external sub-advisors. Research and trading execution run through Mathis and a small internal team, consistent with the firm's low-client-count, high-concentration model.

The firm typically holds between 8 and 15 positions, with multi-year holding periods and annual turnover measured in single-digit percentages. This level of concentration is deliberate and communicated explicitly to prospective clients as a feature, not a bug, of the strategy.

No. The firm runs a long-only public equity strategy and does not participate in venture capital, private equity, real estate, or hedge fund allocations. This singles-asset-class mandate distinguishes it from most multi-family offices and wealth management platforms serving technology wealth.

Financial Advantage Advisors employs a fee structure aligned with long-term compounding outcomes rather than asset gathering, charging a management fee on assets under advisement. The firm does not charge performance fees, does not receive placement fees from fund managers, and does not participate in revenue-sharing arrangements with product providers.

Clients come almost entirely through Bay Area technology networks and word-of-mouth referral. The firm does not market, does not maintain institutional consultant relationships, and does not appear on retail advisor platforms. Its client base consists of founders, early employees, and executives who self-select into the concentrated, long-duration philosophy.

Financial Advantage Advisors is structured as a registered investment advisor (RIA). While it serves families and operates with some family-office characteristics, it does not offer the bundled tax, estate, or concierge services that define full multi-family office platforms. Its value proposition is confined to concentrated public equity portfolio management.

The firm avoids sectors where it lacks domain advantage, including energy and commodities, materials, deep cyclicals, and capital-intensive industrials. It also avoids biotechnology, where binary FDA-outcome risk is incompatible with the concentrated-portfolio structure, and anything requiring leverage or shorting to generate returns.